7XP Stock Overview
Develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women’s health in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 1/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Organon & Co. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$16.64 |
| 52 Week High | US$21.56 |
| 52 Week Low | US$10.15 |
| Beta | 0.81 |
| 1 Month Change | 0% |
| 3 Month Change | -2.23% |
| 1 Year Change | -9.91% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -43.09% |
Recent News & Updates
Recent updates
Shareholder Returns
| 7XP | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | -0.3% | -0.3% |
| 1Y | -9.9% | -17.0% | 7.0% |
Return vs Industry: 7XP exceeded the German Pharmaceuticals industry which returned -19.5% over the past year.
Return vs Market: 7XP underperformed the German Market which returned 2.7% over the past year.
Price Volatility
| 7XP volatility | |
|---|---|
| 7XP Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 7XP has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 7XP's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 10,000 | Kevin Ali | www.organon.com |
Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women’s health in the United States and internationally. Its women’s health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company’s biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio.
Organon & Co. Fundamentals Summary
| 7XP fundamental statistics | |
|---|---|
| Market cap | €4.90b |
| Earnings (TTM) | €957.80m |
| Revenue (TTM) | €5.81b |
5.1x
P/E Ratio0.8x
P/S RatioIs 7XP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7XP income statement (TTM) | |
|---|---|
| Revenue | US$6.35b |
| Cost of Revenue | US$2.60b |
| Gross Profit | US$3.75b |
| Other Expenses | US$2.70b |
| Earnings | US$1.05b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 06, 2024
| Earnings per share (EPS) | 4.07 |
| Gross Margin | 59.04% |
| Net Profit Margin | 16.50% |
| Debt/Equity Ratio | 18,154.2% |
How did 7XP perform over the long term?
See historical performance and comparisonDividends
5.4%
Current Dividend Yield27%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/07/17 13:36 |
| End of Day Share Price | 2024/04/19 00:00 |
| Earnings | 2024/03/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Organon & Co. is covered by 15 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Balaji Prasad | Barclays |
| Balaji Prasad | Barclays |
| Navann Ty Dietschi | BNP Paribas Exane |